MedTrace Logo

Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients

NCT00969306 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2019-02-15

No results posted yet for this study

Summary

Chloroquine might very well be able to increase overall survival in small cell lung cancer by sensitizing cells resistant to chemotherapy and radiotherapy.

Conditions

Interventions

DRUG

Chloroquine, A-CQ 100

Administration: * Orally * Timing: Once daily * Tablets of 100 mg * During or after meals * In case of missed dose: intake of the missed dose is still possible up until 12 hours before the next dose. * Patients should always note date and time of intake on the chloroquine monitoring form.

Sponsors & Collaborators

  • Maastricht University Medical Center

    collaborator OTHER

  • National Cancer Institute (NCI)

    collaborator NIH

  • Maastricht Radiation Oncology

    lead OTHER

Principal Investigators

  • Philippe Lambin, DM, PhD · Maastricht Radiation Oncology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00969306 on ClinicalTrials.gov